Crystal Structure of the Parasite Inhibitor Chagasin In

Total Page:16

File Type:pdf, Size:1020Kb

Crystal Structure of the Parasite Inhibitor Chagasin In Crystal structure of the parasite inhibitor chagasin in complex with papain allows identification of structural requirements for broad reactivity and specificity determinants for target proteases Izabela Redzynia1,*, Anna Ljunggren2,*, Anna Bujacz1, Magnus Abrahamson2, Mariusz Jaskolski3,4 and Grzegorz Bujacz1,4 1 Institute of Technical Biochemistry, Faculty of Biotechnology and Food Sciences, Technical University of Lodz, Poland 2 Department of Laboratory Medicine, Division of Clinical Chemistry and Pharmacology, Lund University, Sweden 3 Department of Crystallography, Faculty of Chemistry, A. Mickiewicz University, Poznan, Poland 4 Center for Biocrystallographic Research, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland Keywords A complex of chagasin, a protein inhibitor from Trypanosoma cruzi, and Chagas disease; cruzipain; cysteine papain, a classic family C1 cysteine protease, has been crystallized. Kinetic proteases; papain; protein inhibitors studies revealed that inactivation of papain by chagasin is very fast ) ) (k = 1.5 · 106 m 1Æs 1), and results in the formation of a very tight, Correspondence on m G. Bujacz, Institute of Technical Biochemis- reversible complex (Ki =36p ), with similar or better rate and equilib- try, Faculty of Biotechnology and Food rium constants than those for cathepsins L and B. The high-resolution Sciences, Technical University of Lodz, ul. crystal structure shows an inhibitory wedge comprising three loops, which Stefanowskiego 4/10, 90-924 Lodz, Poland forms a number of contacts responsible for the high-affinity binding. Com- Fax: +48 42 636 66 18 parison with the structure of papain in complex with human cystatin B Tel: +48 42 631 34 31 reveals that, despite entirely different folding, the two inhibitors utilize very E-mail: [email protected] similar atomic interactions, leading to essentially identical affinities for the M. Abrahamson, Department of Laboratory Medicine, Division of Clinical Chemistry and enzyme. Comparisons of the chagasin–papain complex with high-resolution Pharmacology, Lund University, University structures of chagasin in complexes with cathepsin L, cathepsin B and falci- Hospital, SE-221 85 Lund, Sweden pain allowed the creation of a consensus map of the structural features that Fax: +46 46 130064 are important for efficient inhibition of papain-like enzymes. The compari- Tel: +46 46 173445 sons also revealed a number of unique interactions that can be used to E-mail: [email protected] design enzyme-specific inhibitors. As papain exhibits high structural simi- larity to the catalytic domain of the T. cruzi enzyme cruzipain, the present *These authors contributed equally to this paper chagasin–papain complex provides a reliable model of chagasin–cruzipain interactions. Such information, coupled with our identification of specifi- Database city-conferring interactions, should be important for the development of Atomic coordinates, together with structure drugs for treatment of the devastating Chagas disease caused by this factors, have been deposited in the Protein parasite. Data Bank under the accession code 3E1Z (Received 13 October 2008, revised 15 November 2008, accepted 1 December 2008) doi:10.1111/j.1742-4658.2008.06824.x Papain (EC 3.4.22.2) from the latex of the papaya fruit studies in the 20th century peaked with efforts in the (Carica papaya) was one of the first known proteolytic 1960s, defining the chemistry of the enzymatic mecha- enzymes, and its digestive properties were already nism, delineating the concept of specificity for protein being utilized in the 19th century. Detailed biochemical substrate recognition [1–3], and with elucidation of the FEBS Journal (2008) ª 2008 The Authors Journal compilation ª 2008 FEBS 1 Chagasin–papain complex structure I. Redzynia et al. crystal structure of the enzyme, one of the first protein binding epitope of chagasin consists of three loops structures to be determined [4]. Since then, papain has (L4, L2, L6) that together form a wedge-like enzyme- been used as a model protein in many studies, and is binding epitope. the founding member of the large C1 family of In this study, we present a high-quality crystal papain-like cysteine proteases [5]. Approximately 12 structure of chagasin in complex with papain, the mammalian cysteine proteases are evolutionarily clo- model C1 family cysteine protease and one of only sely related to papain and hence belong to this family two enzymes in the family for which structural infor- (e.g. cathepsins B, H, L, S and K). Enzymes from the mation for a cystatin complex is available [23,24]. C1 family generally function in every cell as compo- Based on the amino acid sequence and structure-based nents of the lysosomal degradation system, participat- alignment, papain has been shown to be a close ing in the turnover of proteins, but, in addition, have homolog of cruzipain [25]. Our results confirm map- been shown to participate in a number of specialized ping of the enzyme-binding epitope to the three loops, functions, such as proteolytic cleavages activating pro- as in chagasin complexes with mammalian enzymes, hormones, regulation of antigen presentation, etc. C1 and illustrate the degree of structural adjustments as family proteases are evolutionarily old, are found in well as precise atomic contacts formed during enzyme both prokaryotic and eukaryotic organisms, and in binding. Moreover, comparative analysis of several many cases show activity that is indispensable for the chagasin complexes has revealed a strikingly similar organism. The unicellular parasite Trypanosoma cruzi core structure involved in enzyme binding, which is an example of such an organism, in which the results in sub-nanomolar Ki values and rate constants papain-like enzyme, cruzipain, is essential for the life- for inactivation in the 105–106 m)1Æs)1 range in all cycle of the parasite and also acts as a virulence factor cases. Additionally, several contacts unique to the when the parasite infects its human host, causing the individual enzyme complexes could be identified, rais- devastating Chagas disease [6,7]. ing the prospect of accurate structure-aided design of In a variety of species, from mammals, plants and specific inhibitors of cruzipain and cathepsins. insects to simpler eukaryotes such as the filarial Detailed knowledge of the structure and inhibition parasites Onchocerca volvulus and Acanthocheilonema mode of chagasin should be valuable in guiding the viteae, C1 family cysteine proteases are in equilibrium development of drugs for the prevention and treat- with protein inhibitors belonging to the cystatin fam- ment of Chagas disease. ily, I25 [5,8–10]. Most cystatins, such as human cysta- tin B, are single-domain proteins of 100–120 residues Results with a characteristic wedge-like epitope consisting of the N-terminus and two b-hairpin loops, which blocks Function of chagasin as an inhibitor of papain the active site cleft of the target enzyme, thereby inhib- iting the activity in a reversible manner [11,12]. Cysta- Chagasin used in this study was expressed in Escheri- tins show high affinity for their target enzymes due to chia coli and purified to homogeneity as reported a large binding area, with dissociation constants (Ki)in previously [20]. The recombinant protein contains five the range 10)9–10)11 m. In extreme cases, such as the extra N-terminal amino acid residues from the expres- human cystatin C–papain complex, Ki values as low as sion construct, and has a mass of 12 440 Da as 10)14 m have been reported [13]. expected [20]. The protein shows almost 100% activity Trypanosomatids, such as various Trypanosoma and as a protease inhibitor based on titration of a papain Leishmania species, produce inhibitors of their own solution with known activity, forms stoichiometric family C1 proteases [14]. Chagasin, a tight-binding 1 : 1 complexes with cathepsin L or B, and is not inhibitor of cruzipain found in T. cruzi [15], exhibits cleaved by these proteases [20,21]. no sequence similarity with cystatins (GenBank ⁄ EMBL Kinetic parameters for the interaction of chagasin [16] accession number AJ299433), despite its similar with papain at pH 6.0 were determined in a continuous- size (110 residues). Molecular modeling studies pre- rate assay using the sensitive fluorogenic substrate car- dicted an immunoglobulin-like fold for chagasin [17], boxybenzoyl-Phe-Arg-7-(4-methyl)coumarylamide, with which was essentially confirmed by subsequent NMR a sufficiently high inhibitor concentration for the [18] and crystallographic studies [19,20]. Recently, crys- binding reaction to be of pseudo-first order. The kon ) ) tal structures of chagasin in complex with human cath- value was determined to be 1.5 · 106 m 1Æs 1, very simi- epsins L and B [20,21], and additionally with falcipain lar to that determined for cathepsin L and higher than from the malaria parasite [22], have been determined. that for cathepsin B under the same conditions The complex structures demonstrate that the enzyme- (Table 1). The equilibrium constant for dissociation 2 FEBS Journal (2008) ª 2008 The Authors Journal compilation ª 2008 FEBS I. Redzynia et al. Chagasin–papain complex structure Table 1. Function of chagasin as an inhibitor of papain and other Table 2. Data collection and structure refinement statistics. C1 family enzymes. Equilibrium constants for dissociation (Ki)of chagasin–papain complexes were determined under steady-state Data collection conditions at pH 6.0 as described in Experimental procedures. Cor- Radiation source X13, EMBL Hamburg ˚ responding values for the papain-like cysteine proteases cathep- Wavelength (A) 0.8086 sin L, cathepsin B and falcipain, with known inhibitor complex Temperature of measurements (K) 100 structures [20–22], as well as for the papain complex with human Space group I422 Cell parameters (A˚ ) a = 99.1, c = 159.5 cystatin B [12], are included for comparison. The Ki values pre- ˚ a sented were corrected for substrate competition in the assays, as Resolution range (A) 60.0–1.86 (1.93–1.86) described in Experimental procedures. ND, not determined.
Recommended publications
  • Cystatins in Immune System
    Journal of Cancer 2013, Vol. 4 45 Ivyspring International Publisher Journal of Cancer 2013; 4(1): 45-56. doi: 10.7150/jca.5044 Review Cystatins in Immune System Špela Magister1 and Janko Kos1,2 1. Jožef Stefan Institute, Department of Biotechnology, Ljubljana, Slovenia; 2. University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia. Corresponding author: Janko Kos, Ph. D., Department of Biotechnology, Jožef Stefan Institute, &Faculty of Pharmacy, University of Ljubljana, Slovenia; [email protected]; Phone+386 1 4769 604, Fax +3861 4258 031. © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2012.10.22; Accepted: 2012.12.01; Published: 2012.12.20 Abstract Cystatins comprise a large superfamily of related proteins with diverse biological activities. They were initially characterised as inhibitors of lysosomal cysteine proteases, however, in recent years some alternative functions for cystatins have been proposed. Cystatins pos- sessing inhibitory function are members of three families, family I (stefins), family II (cystatins) and family III (kininogens). Stefin A is often linked to neoplastic changes in epithelium while another family I cystatin, stefin B is supposed to have a specific role in neuredegenerative diseases. Cystatin C, a typical type II cystatin, is expressed in a variety of human tissues and cells. On the other hand, expression of other type II cystatins is more specific. Cystatin F is an endo/lysosome targeted protease inhibitor, selectively expressed in immune cells, suggesting its role in processes related to immune response.
    [Show full text]
  • Anti-Cystatin B / Stefin B Antibody (ARG56897)
    Product datasheet [email protected] ARG56897 Package: 100 μl anti-Cystatin B / Stefin B antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes Cystatin B / Stefin B Tested Reactivity Hu Tested Application ICC/IF, IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name Cystatin B / Stefin B Antigen Species Human Immunogen Recombinant fusion protein corresponding to aa. 1-98 of Human Cystatin B / Stefin B (NP_000091.1). Conjugation Un-conjugated Alternate Names Liver thiol proteinase inhibitor; EPM1; CPI-B; EPM1A; Cystatin-B; Stefin-B; PME; CST6; ULD; STFB Application Instructions Application table Application Dilution ICC/IF 1:50 - 1:200 IHC-P 1:50 - 1:200 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control MCF7 and DU145 Calculated Mw 11 kDa Observed Size 14 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/3 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol CSTB Gene Full Name cystatin B (stefin B) Background The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences.
    [Show full text]
  • Stefin B (CSTB) Mouse Monoclonal Antibody [Clone ID: OTI1E8] Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA813046 Stefin B (CSTB) Mouse Monoclonal Antibody [Clone ID: OTI1E8] Product data: Product Type: Primary Antibodies Clone Name: OTI1E8 Applications: IHC, WB Recommended Dilution: WB 1:500, IHC 1:500 Reactivity: Human Host: Mouse Isotype: IgG1 Clonality: Monoclonal Immunogen: Human recombinant protein fragment corresponding to amino acids 1-98 of human CSTB (NP_000091) produced in E.coli. Formulation: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. Concentration: 1 mg/ml Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 11 kDa Gene Name: cystatin B Database Link: NP_000091 Entrez Gene 1476 Human P04080 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Stefin B (CSTB) Mouse Monoclonal Antibody [Clone ID: OTI1E8] – TA813046 Background: The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and kininogens. This gene encodes a stefin that functions as an intracellular thiol protease inhibitor.
    [Show full text]
  • Neutrophil Chemoattractant Receptors in Health and Disease: Double-Edged Swords
    Cellular & Molecular Immunology www.nature.com/cmi REVIEW ARTICLE Neutrophil chemoattractant receptors in health and disease: double-edged swords Mieke Metzemaekers1, Mieke Gouwy1 and Paul Proost 1 Neutrophils are frontline cells of the innate immune system. These effector leukocytes are equipped with intriguing antimicrobial machinery and consequently display high cytotoxic potential. Accurate neutrophil recruitment is essential to combat microbes and to restore homeostasis, for inflammation modulation and resolution, wound healing and tissue repair. After fulfilling the appropriate effector functions, however, dampening neutrophil activation and infiltration is crucial to prevent damage to the host. In humans, chemoattractant molecules can be categorized into four biochemical families, i.e., chemotactic lipids, formyl peptides, complement anaphylatoxins and chemokines. They are critically involved in the tight regulation of neutrophil bone marrow storage and egress and in spatial and temporal neutrophil trafficking between organs. Chemoattractants function by activating dedicated heptahelical G protein-coupled receptors (GPCRs). In addition, emerging evidence suggests an important role for atypical chemoattractant receptors (ACKRs) that do not couple to G proteins in fine-tuning neutrophil migratory and functional responses. The expression levels of chemoattractant receptors are dependent on the level of neutrophil maturation and state of activation, with a pivotal modulatory role for the (inflammatory) environment. Here, we provide an overview
    [Show full text]
  • Role of Extracellular Proteases in Biofilm Disruption of Gram Positive
    e Engine ym er z in n g E Mukherji, et al., Enz Eng 2015, 4:1 Enzyme Engineering DOI: 10.4172/2329-6674.1000126 ISSN: 2329-6674 Review Article Open Access Role of Extracellular Proteases in Biofilm Disruption of Gram Positive Bacteria with Special Emphasis on Staphylococcus aureus Biofilms Mukherji R, Patil A and Prabhune A* Division of Biochemical Sciences, CSIR-National Chemical Laboratory, Pune, India *Corresponding author: Asmita Prabhune, Division of Biochemical Sciences, CSIR-National Chemical Laboratory, Pune 411008, India, Tel: 91-020-25902239; Fax: 91-020-25902648; E-mail: [email protected] Rec date: December 28, 2014, Acc date: January 12, 2015, Pub date: January 15, 2015 Copyright: © 2015 Mukherji R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Bacterial biofilms are multicellular structures akin to citadels which have individual bacterial cells embedded within a matrix of a self-synthesized polymeric or proteinaceous material. Since biofilms can establish themselves on both biotic and abiotic surfaces and that bacteria residing in these complex molecular structures are much more resistant to antimicrobial agents than their planktonic equivalents, makes these entities a medical and economic nuisance. Of late, several strategies have been investigated that intend to provide a sustainable solution to treat this problem. More recently role of extracellular proteases in disruption of already established bacterial biofilms and in prevention of biofilm formation itself has been demonstrated. The present review aims to collectively highlight the role of bacterial extracellular proteases in biofilm disruption of Gram positive bacteria.
    [Show full text]
  • Cysteine Proteinases of Microorganisms and Viruses
    ISSN 00062979, Biochemistry (Moscow), 2008, Vol. 73, No. 1, pp. 113. © Pleiades Publishing, Ltd., 2008. Original Russian Text © G. N. Rudenskaya, D. V. Pupov, 2008, published in Biokhimiya, 2008, Vol. 73, No. 1, pp. 317. REVIEW Cysteine Proteinases of Microorganisms and Viruses G. N. Rudenskaya1* and D. V. Pupov2 1Faculty of Chemistry and 2Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia; fax: (495) 9393181; Email: [email protected] Received May 7, 2007 Revision received July 18, 2007 Abstract—This review considers properties of secreted cysteine proteinases of protozoa, bacteria, and viruses and presents information on the contemporary taxonomy of cysteine proteinases. Literature data on the structure and physicochemical and enzymatic properties of these enzymes are reviewed. High interest in cysteine proteinases is explained by the discovery of these enzymes mostly in pathogenic organisms. The role of the proteinases in pathogenesis of several severe diseases of human and animals is discussed. DOI: 10.1134/S000629790801001X Key words: cysteine proteinases, properties, protozoa, bacteria, viruses Classification and Catalytic Mechanism papain and related peptidases showed that the catalytic of Cysteine Proteinases residues are arranged in the following order in the polypeptide chain: Cys, His, and Asn. Also, a glutamine Cysteine proteinases are peptidyl hydrolases in residue preceding the catalytic cysteine is also important which the role of the nucleophilic group of the active site for catalysis. This residue is probably involved in the for is performed by the sulfhydryl group of a cysteine residue. mation of the oxyanion cavity of the enzyme. The cat Cysteine proteinases were first discovered and investigat alytic cysteine residue is usually followed by a residue of ed in tropic plants.
    [Show full text]
  • 1 Supporting Information for a Microrna Network Regulates
    Supporting Information for A microRNA Network Regulates Expression and Biosynthesis of CFTR and CFTR-ΔF508 Shyam Ramachandrana,b, Philip H. Karpc, Peng Jiangc, Lynda S. Ostedgaardc, Amy E. Walza, John T. Fishere, Shaf Keshavjeeh, Kim A. Lennoxi, Ashley M. Jacobii, Scott D. Rosei, Mark A. Behlkei, Michael J. Welshb,c,d,g, Yi Xingb,c,f, Paul B. McCray Jr.a,b,c Author Affiliations: Department of Pediatricsa, Interdisciplinary Program in Geneticsb, Departments of Internal Medicinec, Molecular Physiology and Biophysicsd, Anatomy and Cell Biologye, Biomedical Engineeringf, Howard Hughes Medical Instituteg, Carver College of Medicine, University of Iowa, Iowa City, IA-52242 Division of Thoracic Surgeryh, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada-M5G 2C4 Integrated DNA Technologiesi, Coralville, IA-52241 To whom correspondence should be addressed: Email: [email protected] (M.J.W.); yi- [email protected] (Y.X.); Email: [email protected] (P.B.M.) This PDF file includes: Materials and Methods References Fig. S1. miR-138 regulates SIN3A in a dose-dependent and site-specific manner. Fig. S2. miR-138 regulates endogenous SIN3A protein expression. Fig. S3. miR-138 regulates endogenous CFTR protein expression in Calu-3 cells. Fig. S4. miR-138 regulates endogenous CFTR protein expression in primary human airway epithelia. Fig. S5. miR-138 regulates CFTR expression in HeLa cells. Fig. S6. miR-138 regulates CFTR expression in HEK293T cells. Fig. S7. HeLa cells exhibit CFTR channel activity. Fig. S8. miR-138 improves CFTR processing. Fig. S9. miR-138 improves CFTR-ΔF508 processing. Fig. S10. SIN3A inhibition yields partial rescue of Cl- transport in CF epithelia.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Best Presentation
    Survey of Public Showed Preference for Healthcare Environ Diagnostic ment 15% Energy Healthca 13% re 47% Food & Nutrition 15% Others 11% Chagas Disease – Our Real World Problem Chagas Disease – Our Real World Problem “Chagas disease, caused by the protozoan Trypanosoma cruzi, is responsible for a greater disease burden than any other parasitic disease in the New World” Limitations in Diagnostics Immunocompromised Coinfection with HIV Infants Variable efficiency Evolution of surface antigens Differences between strains Investigating the Feasibility of Our Diagnostics Would screening all infants impact epidemiology? Would our diagnostic be a viable investment? Can our project make a real difference? Prof Yves Carlier, expert in Infectious Diseases (Université Libre de Bruxelles) Provided us with useful insights into Chagas disease throughout our project Epidemiological Model Shows a Congenital Chagas Diagnostic is Viable Total infected without diagnostic Population Total infected with diagnostic Years Epidemiological Model Shows a Congenital Chagas Diagnostic is Viable Total infected >130,000 fewer infected individuals without diagnostic $61 mil in healthcare costs saved annually Total infected with Population diagnostic 37,000 DALYs per year eliminated Years Prof Mike Bonsall, Professor of Mathematical Biology (University of Oxford) Helped us gain a better understanding of the principles of disease modelling, and equipped us with the skills to create our own epidemiological model for Chagas disease Canonical Diagnostic Circuitry INPUT CIRCUIT
    [Show full text]
  • Morelloflavone and Its Semisynthetic Derivatives As Potential Novel Inhibitors of Cysteine and Serine Proteases
    See discussions, stats, and author profiles for this publication at: http://www.researchgate.net/publication/276087209 Morelloflavone and its semisynthetic derivatives as potential novel inhibitors of cysteine and serine proteases ARTICLE in JOURNAL OF MEDICINAL PLANT RESEARCH · APRIL 2015 Impact Factor: 0.88 · DOI: 10.5897/JMPR2014.5641 DOWNLOADS VIEWS 2 17 8 AUTHORS, INCLUDING: Ihosvany Camps Claudio Viegas-jr Universidade Federal de Alfenas Universidade Federal de Alfenas 35 PUBLICATIONS 128 CITATIONS 6 PUBLICATIONS 22 CITATIONS SEE PROFILE SEE PROFILE Available from: Ihosvany Camps Retrieved on: 08 September 2015 Vol. 9(13), pp. 426-434, 3 April, 2015 DOI: 10.5897/JMPR2014.5641 Article Number: A42115152263 ISSN 1996-0875 Journal of Medicinal Plants Research Copyright © 2015 Author(s) retain the copyright of this article http://www.academicjournals.org/JMPR Full Length Research Paper Morelloflavone and its semisynthetic derivatives as potential novel inhibitors of cysteine and serine proteases Vanessa Silva Gontijo1, Jaqueline Pereira Januário1, Wagner Alves de Souza Júdice2, Alyne Alexandrino Antunes2, Ingridy Ribeiro Cabral1, Diego Magno Assis3, Maria Aparecida Juliano3, Ihosvany Camps4, Marcos José Marques4, Claudio Viegas Junior1 and Marcelo Henrique dos Santos1* 1Department of Exact Science, Laboratory of Phytochemistry and Medicinal Chemistry, Federal University of Alfenas, MG, Brazil. 2Interdisciplinary Center of Biochemical Investigation, Mogi das Cruzes University, Mogi das Cruzes, SP, Brazil. 3Department of Biophysics, Federal University of São Paulo, SP, Brazil. 4Department of Biological Sciences, Laboratory of Molecular Biology, Federal University of Alfenas, MG, Brazil. Received 9 October, 2014; Accepted 11 March, 2015 This article reports the three biflavonoids isolated from the fruit pericarp of Garcinia brasiliensis Mart.
    [Show full text]
  • Genomic Profiling of Short- and Long-Term Caloric Restriction Effects in the Liver of Aging Mice
    Genomic profiling of short- and long-term caloric restriction effects in the liver of aging mice Shelley X. Cao, Joseph M. Dhahbi, Patricia L. Mote, and Stephen R. Spindler* Department of Biochemistry, University of California, Riverside, CA 92521 Edited by Bruce N. Ames, University of California, Berkeley, CA, and approved July 11, 2001 (received for review June 19, 2001) We present genome-wide microarray expression analysis of 11,000 aging and CR on gene expression. Control young (7-month-old; n ϭ genes in an aging potentially mitotic tissue, the liver. This organ has 3) and old (27-month-old; n ϭ 3) mice were fed 95 kcal of a a major impact on health and homeostasis during aging. The effects semipurified control diet (Harlan Teklad, Madison, WI; no. of life- and health-span-extending caloric restriction (CR) on gene TD94145) per week after weaning. Long-term CR (LT-CR) young expression among young and old mice and between long-term CR (7-month-old; n ϭ 3) and old (27-month-old; n ϭ 3) mice were fed (LT-CR) and short-term CR (ST-CR) were examined. This experimental 53 kcal of a semipurified CR diet (Harlan Teklad; no. TD94146) per design allowed us to accurately distinguish the effects of aging from week after weaning. Short-term CR (ST-CR) mice were 34-month- those of CR on gene expression. Aging was accompanied by changes old control mice that were switched to 80 kcal of CR diet for 2 in gene expression associated with increased inflammation, cellular weeks, followed by 53 kcal for 2 weeks (n ϭ 3).
    [Show full text]
  • Cystatin B: Mutation Detection, Alternative Splicing and Expression in Progressive Myclonus Epilepsy of Unverricht-Lundborg Type (EPM1) Patients
    European Journal of Human Genetics (2007) 15, 185–193 & 2007 Nature Publishing Group All rights reserved 1018-4813/07 $30.00 www.nature.com/ejhg ARTICLE Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients Tarja Joensuu*,1, Mervi Kuronen1, Kirsi Alakurtti1, Saara Tegelberg1, Paula Hakala1, Antti Aalto2, Laura Huopaniemi3, Nina Aula1, Roberto Michellucci4, Kai Eriksson5 and Anna-Elina Lehesjoki1 1Department of Medical Genetics and Neuroscience Center, Folkha¨lsan Institute of Genetics, Biomedicum Helsinki, University of Helsinki, Finland; 2Institute of Biotechnology, Viikki Biocenter, University of Helsinki, Finland; 3Rational Drug Design Program, Biomedicum Helsinki, Helsinki, Finland; 4Department of Neurosciences, Epilepsy Centre, Bellaria Hospital, Bologna, Italy; 5Pediatric Neurology Unit, Department of Pediatrics, Pediatric Research Center, Medical School, University of Tampere and Tampere University Hospital, Tampere, Finland Progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1) is an autosomal recessive neurodegenerative disorder caused by mutations in the cystatin B gene (CSTB) that encodes an inhibitor of several lysosomal cathepsins. An unstable expansion of a dodecamer repeat in the CSTB promoter accounts for the majority of EPM1 disease alleles worldwide. We here describe a novel PCR protocol for detection of the dodecamer repeat expansion. We describe two novel EPM1-associated mutations, c.149G4A leading to the p.G50E missense change and an intronic 18-bp deletion (c.168 þ 1_18del), which affects splicing of CSTB. The p.G50E mutation that affects the conserved QVVAG amino acid sequence critical for cathepsin binding fails to associate with lysosomes. This further supports the previously implicated physiological importance of the CSTB-lysosome association.
    [Show full text]